BLAINJECTIONINJECTABLE
Approved
Apr 2024
Lifecycle
Growth
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 6h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SELARSDI is a monoclonal antibody biosimilar to ustekinumab (STELARA), approved by the FDA on April 16, 2024, as a Biologics License Application (BLA). It is manufactured by Alvotech and represents a biosimilar entry into the ustekinumab market for immunological indications. The drug mechanism targets IL-12 and IL-23 pathways to modulate immune response.
Growth
As a newly approved biosimilar in the growth phase, SELARSDI will build commercial infrastructure and capture market share through payer contracting and provider education initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
SELARSDI offers opportunities primarily in manufacturing, quality, compliance, and pharmacovigilance functions reflecting Alvotech's biosimilar manufacturing operations and post-approval regulatory obligations. Career growth on this product is driven by operational excellence and market penetration rather than clinical innovation, with 12 linked job openings across support functions.
Specialist
Worked on SELARSDI at Alvotech? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.